Introduction
============

Parkinson disease (PD) results from progressive degeneration of dopaminergic neurons in the midbrain. PD is characterized by resting tremor, bradykinesia, and muscle rigidity [@B1]. At present, no treatment can protect PD-susceptible neurons or prevent the disease from progression, although dopamine replenishment therapy temporally alleviates PD symptoms [@B2], [@B3]. Limited knowledge of PD pathogenesis is a major roadblock in the development of effective therapy for this devastating disease. Recent advance in epidemiological studies suggests PD as a multifactorial disease. Aging, genetic and environmental factors are considered risky for PD, but how these risk factors interact to cause the disease remains largely unknown.

Occupational exposure to pesticides and cumulative exposure to the herbicide paraquat increase the risk of developing PD [@B4], [@B5]. Repeated exposure to environmental toxicants is associated with the increased risk of PD, but no single environmental toxicant has been definitively linked to PD, suggesting that the other risk factors must be involved in the development of sporadic PD. Genetic factors influence the susceptibility to PD. The relatives of PD patients show an increased incidence of PD [@B6]. While most PD cases are sporadic, about 10% of the cases have pathogenic mutations in the individual genes including *alpha-synuclein*, *Leucine-Rich Repeat Kinase 2* (*LRRK2*), *parkin*, *DJ-1*, and *PTEN-induced putative kinase 1*(*PINK1*) [@B7]-[@B13]. Intriguingly, some PD patients carry mutation only in the one allele of the recessive genes *parkin* and *PINK1* and some people carrying mutation in the dominant gene *LRRK2* do not develop PD in their lives [@B14]-[@B16]. The penetrance and expressivity of PD phenotypes appears to be determined not only by pathogenic mutation in the identified genes, but also by undefined factors.

Dysfunction of neuron-protective genes and exposure to toxicants may corporate to induce dopaminergic neurodegeneration in sporadic PD. Indeed, deletion of the neuron-protective genes such as *parkin*, *DJ-1*, and *PINK1*sensitizes dopaminergic neurons to the toxicants MPTP and paraquat [@B17]-[@B24]. Most sporadic PD cases do not have genetic mutation, but they may suffer from partial dysfunction of neuron-protective genes later in lives. For example, Parkin is S-nitrosylated in PD animal models and in PD patients [@B25], [@B26]. S-nitrosylation inhibits Parkin ligase activity and induces accumulation of improperly folded and biologically inactive protein, causing a loss of the neuron-protective functions of Parkin. As aging, some neuron-protective genes may be partially inactivated due to epigenetic modification. Exposure to environmental toxicants and genetic failure may not occur concomitantly, but may occur sequentially. Perhaps, exposure to environmental toxicants early in the life causes accumulative effects and sensitizes dopaminergic neurons to the partial dysfunction of neuron-protective genes later in the life, causing sporadic PD. To obtain the partial dysfunction of a neuron-protective gene temporally in adult mice, we created conditional PINK1-RNAi transgenic mice, which were treated with paraquat before the *PINK1* gene was partially silenced in the adulthood. We observed that early exposure to the environmental toxicant paraquat sensitized dopaminergic neurons to subsequent dysfunction of the *PINK1* gene.

Materials and Methods
=====================

Transgenic mice and behavioral analysis
---------------------------------------

PINK1 RNAi transgenic mice have been characterized [@B27]. Tamoxifen inducible Cre (CreERT) transgenic mice were purchased from Jackson Laboratories [@B28]. Cre was driven by the ubiquitous hybrid promoter CAG and was expressed in all tissues [@B28]. To minimize the leakage of Cre activity, male CreERT mice were crossed with female PINK1-RNAi mice to produce doubly transgenic offspring. Transgenic mice were identified by PCR analysis of tail DNA as described previously [@B27]. As stated in the results, paraquat (Sigma) was administered to transgenic mice at the age of 14 days (0.3 mg/kg, subcutaneous injection; once) or at the age of 12 weeks (10mg/kg, twice a week, for 3 consecutive weeks). To induce a marked neurotoxicity, paraquat was repeatedly administered to selected mice at the postnatal ages and again in the adulthood. At the age of 16 weeks, selected mice were injected with 4-hydroxyl Tamoxifen (4-OHT; Sigma) to induce Cre activity and thus to activate PINK1 RNAi transgene. To achieve a full activation of PINK1 RNAi transgene, 4-OHT was administered by intraperitoneal injection for 5 consecutive days (50 mg/kg/day). The locomotor activity of transgenic mice within 30 minutes was measured by open field activity assay (Med Associates). Animal use followed NIH guidelines and the animal use protocol was approved by the Institutional Animal Care and Use Committees at the University.

Microdialysis and HPLC analysis
-------------------------------

As described previously [@B29], the extracellular level of dopamine released into the striatum was measured by intra-brain microdialysis combined with HPLC. Anesthetized mice were implanted with a guide cannula the day before dialysis. On the following day, dialysis probe (BASi) was inserted through the guide cannula into the left striatum (coordinates: 0.5 mm anterior to bregma; 2 mm left from sagittal line; 1.5 mm ventral to the skull). Continuous perfusion was maintained with modified Ringer\'s solution (147 mm Na^+^, 4 mm K^+^, 1.3 mm Ca^2+^, 1 mm Mg^2+^, and 155.6 mm CI^-^). Dialysates were continuously collected and the dialysates of every 20-minute were pooled as one sample for HPLC analysis. Basal dopamine release was established within two hours when comparable levels of dopamine released were obtained in three consecutive samplings (20 minutes each). The DAT inhibitor nomifensine was applied to dialysis solution (200 µM) for 40 minutes (two samplings) and enhanced dopamine release was then measured. Dopamine concentration in dialysates was instantly measured by HPLC. The content of striatal dopamine was measured by HPLC as described previously [@B27]. Briefly, the striatum was dissected from mouse brain and was homogenized in 0.1 M perchloric acid. Dopamine in cleared lysates was measured by HPLC. Tissue pellets were dissolved in 1M NaOH and protein concentration was determined. The contents of striatal dopamine were adjusted with protein concentration.

Analysis of gene expression by PCR
----------------------------------

PCR was done as described previously [@B30]. In brief, total RNA was isolated from mouse tissues and the total RNA of 1µg was reversely transcribed to cDNA with oligo-dT primer (RT kit, Invitrogen). The resulting cDNA was used PCR amplification. The following primers were used to amplify specific mouse genes: primers 5\'-GCTTGCCAATCCCTTCTATG-3\' (forward) and 5\'-CTCTCGCTGGAGCAGTGAC-3\' (reverse) for PINK1; primers 5\'-CGGTATAATGGTGGAGTTG-3\' (forward) and 5\'-ACCCTTAAGTTCAGCGTTACT-3\' (reverse) for L17; primers 5\'-CAGTGTGGACTTCTACCGTC-3\' (forward) and 5\'-AACTGGAGAAGGCAATCAGC-3\' (reverse) for DAT; And primers 5\'- CTATCCTCATGGACCACAAC-3\' (forward) and 5\'-GCTCAGTCACTCTCAGATTC-3\' (reverse) for VMAT2. Cycling conditions were 2 min at 94°C followed by 26 or 30 cycles of 15 seconds at 94°C, 30 seconds at 60°C, and 20 seconds at 72°C. PCR products were resolved on 2% agarose gels.

Histology and stereological cell counting
-----------------------------------------

TH immunostaining and stereological cell counting were done as described previously [@B27], [@B31]. Mouse brain was cut on a Cryostat into serial sections of 30 µm. Every fourth section through the SNpc was immunostained for TH (Pel-Freez; 1: 1000). TH positive neurons in the SNpc were estimated by stereological cell counting.

Statistical analysis
--------------------

Statistical significance among group means was assessed by ANOVA followed by Tukey\'s post hoc test. In all analyses, the null hypothesis was rejected at the level of 0.05.

Results
=======

Exposure to the herbicide paraquat increases the risk of PD [@B5], and thus we chose paraquat as an example of environmental toxicants. Previous studies showed that repeated exposure to paraquat causes severe damage to dopaminergic system [@B32]. To assess whether early exposure to environmental toxicants sensitizes dopaminergic neurons to later dysfunction of neuron-protective genes, we first determined an optimal dosage of paraquat that is sufficient to induce a moderate loss of dopaminergic neurons in the mouse strains established in our lab (Figure [1](#F1){ref-type="fig"}). We treated male C57BL6 mice with paraquat by subcutaneous injection and observed a moderate, but significant, loss of dopaminergic neurons in the SNpc and a marked depletion of striatal dopamine (Figure [1](#F1){ref-type="fig"}). Some mice were injected of paraquat during postnatal development and again in adulthood and a greater loss of dopaminergic neurons was induced by repeated exposure to paraquat (Figure [1](#F1){ref-type="fig"}). Paraquat caused accumulative damage to dopaminergic neurons in mice. We further examined whether dopaminergic neurotransmission would be compensated in wildtype mice after the toxicant is removed. As expected, lost dopaminergic neurons were never restored (Figure [2](#F2){ref-type="fig"}a). In contrast, synaptic release of dopamine was significantly increased in the mice after paraquat was withdrawn (Figure [2](#F2){ref-type="fig"}b). Synaptic release of dopamine is virtually related to dopaminergic function and thus, the findings suggest that the dopaminergic function may be compensated after the risk factor is removed.

Recessive mutation of the *PINK1* gene is linked to familial PD [@B10]. We chose *PINK1*as an example of neuron-protective genes to examine PD pathogenesis. We have created conditional transgenic mice that express PINK1 RNAi upon Cre-mediated activation of the transgene and display a significant knockdown of *PINK1* gene expression by the RNAi [@B27]. Constitutive depletion of PINK1 by gene knockout or by transgenic RNAi does not induce dopaminergic neuron death in the mutant mice [@B27], [@B33]. To avoid any potential compensation for gene loss during mouse development, we used inducible Cre to activate PINK1 RNAi transgene in adult mice and thus to silence *PINK1* gene expression in the adulthood (Figure [3](#F3){ref-type="fig"}a). Similar to constitutive expression of PINK1 RNAi [@B27], temporal expression of PINK1 RNAi silenced the expression of *PINK1* and did not affect the expression of the *dopamine transporter* (*DAT*) and the *vesicular monoamine transporter*2 (*VMAT2*) genes in transgenic mice (Figure [3](#F3){ref-type="fig"}a). Consistent with constitutive gene silencing [@B27], temporal silencing of *PINK1* gene expression failed to induce dopaminergic neuron death in transgenic mice at advanced ages (Figure [3](#F3){ref-type="fig"}c). Unexpectedly, temporal silencing of *PINK1* gene expression in adult mice increased striatal dopamine and enhanced locomotor activity (Figure [3](#F3){ref-type="fig"}b and [3](#F3){ref-type="fig"}d). The effect of *PINK1* gene silencing on striatal dopamine was diminished as aging (Figure [3](#F3){ref-type="fig"}). Temporal silencing of *PINK1* gene expression in adult mice disturbed dopamine homeostasis, uncovering the phenotypes that were obscured possibly by developmental compensation.

To test whether early exposure to environmental toxicants sensitizes dopaminergic neurons to partial dysfunction of neuron-protective genes, we first administered paraquat to PINK1-RNAi transgenic mice and then silenced the expression of the *PINK1* gene by inducing Cre activity (Figure [3](#F3){ref-type="fig"}a). Surprisingly, a greater depletion of striatal dopamine and dopaminergic neurons was induced by a combination of early exposure to paraquat and subsequent silencing of *PINK1* gene expression, compared to either of the individual treatments (Figure [4](#F4){ref-type="fig"}). The results suggest that environmental exposure and genetic defects may sequentially occur and synergistically induce a progressive degeneration of dopaminergic neurons in PD.

Discussion
==========

Exposure to environmental toxicants, genetic modification of critical genes, and physiological aging are suggested contributing to PD pathogenesis. We showed that repeated exposure to paraquat caused accumulative damage to dopaminergic neurons in mice. By transgenic RNAi, we silenced *PINK1* expression selectively in adult mice and observed a marked change to dopamine homeostasis that could not be induced by constitutive silencing of *PINK1* expression. Early exposure to paraquat sensitized dopaminergic neurons to subsequent silencing of *PINK1* expression in aged mice. Our findings suggest a potential pathogenesis for PD: exposure to environmental toxicants early in the life reduces the threshold of developing PD; partial dysfunction of neuron-protective genes later in the life continuously compromises dopaminergic function and eventually causes the system to cross the reduced threshold of developing PD.

Paraquat is an herbicide commonly used for weed and grass control. Exposure to paraquat is associated with the increased risk of PD [@B5]. In the most studies, paraquat is administered by intraperitoneal injection and few studies [@B32] show a statistically significant loss of striatal dopamine content, although a trend of dopamine loss is always observed. We first tested intraperitoneal injection of paraquat and observed a severe loss of treated mice (data not shown). Compared to intraperitoneal injection of MPTP, subcutaneous injection of MPTP induces a more severe loss of dopaminergic neurons with less variation in phenotypic expression. We then examined the subcutaneous injection of paraquat and observed a significant loss of striatal dopamine content. Our findings in mice are in great consistency with previous findings in rats that are subcutaneously injected with paraquat [@B34]. Intraperitoneal injection may lead to an abrupt absorption of neurotoxicant such as paraquat and cause a remarkable fluctuation of blood and tissue paraquat, leading to varied phenotypes. By contrast, subcutaneous injection of paraquat or MPTP may cause less fluctuation of the chemicals in tissues, producing a relatively constant effect. Consistent with previous findings [@B32], [@B35]-[@B39], our results confirmed that exposure to paraquat caused substantial and accumulative damage to dopaminergic neurons in mice. The detrimental effects of environmental toxicants may accumulate, but may not cause a progressive loss of dopaminergic neurons unless recurrent exposure to toxicants happens frequently. In fact, the reduction in synaptic release of dopamine was partly compensated after paraquat was removed though the lost neurons were never restored. The finding suggests that dopaminergic dysfunction stopped progression after the environmental toxicant was eliminated. Exposure to environmental toxicants reduces the threshold of PD onset, and continuous presence of risk factors is required to induce progressive degeneration of dopaminergic neurons and to cross the reduced threshold of disease onset. Such a lasting insult is likely from an endogenous source in sporadic PD.

As aging, the functions of some neuron-protective genes may be compromised [@B25], [@B26]. While pathogenic mutation of the two *PINK1*alleles definitely causes PD [@B10], mutation of the one *PINK1* allele also increases PD susceptibility [@B40], [@B41], suggesting that PINK1 has dose-dependent effects on dopaminergic neurons. Unlike familial PD, sporadic PD may not have inheritable mutation in neuron-protective genes, but may suffer from partial dysfunction of the beneficial genes later in the life [@B25], [@B26]. In contrast to previous studies [@B42]-[@B44], our study applied transgenic RNAi technology to partially silence the expression of the neuron-protective gene *PINK1* selectively in adult mice. Compared to constitutive gene knockout, temporal silencing of *PINK1*expression in adult mice increased the content of striatal dopamine, possibly because it avoided developmental compensation for the gene loss. Interestingly, simultaneous deletion of *parkin*, *DJ-1*, and *PINK1* also increases striatal dopamine in the triple knockout mice at advanced ages [@B45]. By contrast, deleting any of the three genes (*parkin*, *DJ-1*, and *PINK1*) alone fails to induce the phenotype in the lifetime of single-gene knockout mice [@B33], [@B46]-[@B48]. Intriguingly, striatal dopamine was decreased to the control level in our PINK1-RNAi mice at advanced ages. Alteration to dopamine neurotransmission may be an early event in the process of dopaminergic neurodegeneration.

Given that environmental toxicants cause accumulative damage to dopaminergic neurons, exposure to toxicants any time in the life will reduce the threshold of developing PD and will increase the incidence of PD. Immature brain is vulnerable to neurotoxins [@B32], and exposure to environmental toxicants early in the life may play an important role in PD pathogenesis. Previous studies have shown that complete and constitutive deletion of neuron-protective genes such as *parkin*, *DJ-1*, and *PINK1* sensitizes dopaminergic neurons to neurotoxins [@B17]-[@B24]. Previous studies all test the effects of environmental toxicants on dopaminergic system after a neuroprotective gene is permanently inactivated in mice. By striking contrast, we used a reverse order of gene-environment interaction to examine how PD risky factors corporate to induce the disease. We assessed the effects of early paraquat treatment on the phenotypic expression caused by partial and temporal depletion of the *PINK1*gene, testing a new theory on PD pathogenesis. Conditional transgenic RNAi provides an unprecedented tool for temporal, partial gene depletion in animal models. Temporal silencing of *PINK1* expression by transgenic RNAi induced a significant loss of dopaminergic neurons in aged mice, which received paraquat treatment early in their lives. Endogenous and exogenous toxins may execute toxicity to dopaminergic neurons via varying mechanisms [@B49]-[@B53]. Since RNAi may cause nonspecific toxicity or side-effects, it could not be ruled out whether the outcome in PINK1-RNAi transgenic mice is a combined effect of environmental toxicant, gene silencing, and RNAi toxicity. Regardless of mechanisms, sequential insults from multiple hits may cause accumulative damage to dopaminergic neurons and any lasting insults may initiate a progressive degeneration of dopaminergic neurons, inducing PD onset. The novelty of this hypothetic PD pathogenesis warrants further clinical and epidemiological studies.
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![**Different combination of paraquat and saline was administered to the mice at the postnatal and the adult ages. a,**Stereological cell counting revealed a significant loss of TH-positive neurons in the SNpc of paraquat (PQ)-treated mice. PQ or saline was administered to male mice at the age of 14 days (0.3mg/kg, once) and further at the age of 12 weeks (10mg/kg, twice a week, for 3 consecutive weeks). One week after last PQ injection, the mice were killed for analysis. **b**, HPLC analysis revealed the contents of dopamine in the striatum of PQ-treated and -untreated mice. Data are means ± SEM (n = 7-8). \* *p*\< 0.05 compared to the control mice only injected of saline; \# *p* \< 0.05 compared to the mice injected of paraquat at the age of 14 days.](ijbsv07p1180g01){#F1}

![**Elevation of dopamine release was observed in mice after PQ treatment. a,**Stereological cell counting revealed no progressive loss of TH-positive neurons in PQ-treated mice after paraquat withdrawal. **b**, Intra-striatum microdialysis revealed extracellular levels of dopamine released from dopaminergic terminals. Male mice were injected with PQ at the age of 14 days (0.3mg/kg, once) and further at the age of 12 weeks (10mg/kg, twice a week, for 3 consecutive weeks). Microdialysis was performed in the mice at 1 or 12 weeks after last injection of PQ. By the end of microdialysis, the mice were terminated for stereological cell counting. Data are means ± SEM (n = 5). \* *p*\< 0.05.](ijbsv07p1180g02){#F2}

![**Temporal silencing of *PINK1* expression in adult mice disturbed dopaminergic function. a,**PCR analysis revealed a significant knockdown of *PINK1* expression by RNAi. In CreERT and PINK1-RNAi double transgenic mice, Cre activity was induced by injection of 4-hydroxyl Tamoxifen (4-OHT). Gene expression in the midbrain was analyzed by PCR one month after 4-OHT induction. **b**, Locomotor activity in 30 minutes was measured by open field activity assay. Mice at the age of 16 weeks were treated with 4-OHT to induce gene silencing and were tested for locomotor activity at 10 months and again at 18 months of age. Data are means ± SEM (n = 6). \* *p*\< 0.05. **c,**Stereological cell counting revealed the number of TH-positive neurons in the SNpc. Data are means ± SEM (n = 5). **d**, HPLC measured the contents of striatal dopamine. Mice of individual group were terminated at the age of 10 or 18 months for cell counting. Data are means ± SEM (n = 5). \* *p*\< 0.05.](ijbsv07p1180g03){#F3}

![**Early exposure to paraquat sensitized dopaminergic neurons to subsequent silencing of *PINK1* gene expression. a,**HPLC measured the contents of striatal dopamine in mice. The CreERT single (1, untreated control; 3, paraquat) and the CreERT/PINK1-RNAi double transgenic mice (group 2 and 4) were injected with paraquat or saline at the age of 14 days and further at the age of 12 weeks (10mg/kg, twice a week, for 3 consecutive weeks). One week later, the mice were injected with 4-OHT to induce Cre activity and thus to activate PINK1-RNAi. At the age of 20 months, the mice were terminated for analysis. **b**, Stereological cell counting revealed the number of TH-positive neurons in the SNpc. Data are means ± SEM (n = 10). \* *p*\< 0.05 compared to untreated control; \# *p* \< 0.05 compared to group 3 (paraquat).](ijbsv07p1180g04){#F4}
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